Anti-phosphohistone H3 as an independent prognostic factor in human esophageal squamous cell carcinoma

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 461-468

  Nakashima, Shingo ^a   Shiozaki, Atsushi ^a   Ichikawa, Daisuke ^a   Komatsu, Shuhei ^a   Konishi, Hirotaka ^a   Iitaka, Daisuke ^a   Kubota, Takeshi ^a   Fujiwara, Hitoshi ^a   Okamoto, Kazuma ^a   Kishimoto, Mitsuo ^a   Otsuji, Eigo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Esophageal cancer; Phospho histone H3; Prognostic factor

Indexed keywords

HISTONE H3; KI 67 ANTIGEN; PHOSPHOHISTONE H3; PROTEIN P21; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875904604     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. 2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106(6): 348-360, 1997.
2. Juan G, Traganos F, James WM, Ray JM, Roberge M, Sauve DM, Anderson H and Darzynkiewicz Z: Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry 32(2): 71-77, 1998.
3. Hendzel MJ, Nishioka WK, Raymond Y, Allis CD, Bazett-Jones DP and Th'ng JP: Chromatin condensation is not associated with apoptosis. J Biol Chem 273(38): 24470-24478, 1998.
4. Kim YJ, Ketter R, Steudel WI and Feiden W: Prognostic significance of the mitotic index using the mitosis marker antiphosphohistone H3 in meningiomas. Am J Clin Pathol 128(1): 118-125, 2007.
5. Takei H, Bhattacharjee MB, Rivera A, Dancer Y and Powell SZ: New immunohistochemical markers in the evaluation of central nervous system tumors: A review of 7 selected adult and pediatric brain tumors. Arch Pathol Lab Med 131(2): 234-241, 2007.
6. Ladstein R, Bachmann I, Straume O and Akslen L: Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma. J Invest Dermatol 132: 1247-1252, 2012.
7. Takahashi H, Murai Y, Tsuneyama K, Nomoto K, Okada E, Fujita H and Takano Y: Overexpression of phosphorylated histone H3 is an indicator of poor prognosis in gastric adenocarcinoma patients. Appl Immunohistochem Mol Morphol 14: 296-302, 2006.
8. Goodarzi M, Correa AM, Ajani Jaffer, Swisher SG, Hofstetter WL, Guha Sushovan, Deavers MT, Rashid Asif and Maru DM: Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Modern Pathol 22: 1612-1621, 2009.
9. Aune G, Stunes AK, Tingulstad S, Salvesen Ø, Syversen U and Torp Sverre: The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Int J Clin Exp Pathol 4: 444-453, 2011.
10. Ladstein RG, Bachmann IM, Staume O and Akslen L: Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer 10: 140, 2010.
11. Nasr MR and El-Zammar O: Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 30(2): 117-122, 2008.
12. Williams DJ, Cohen C, Darrow M, Page AJ, Chastain B and Adams AL: Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer. Appl Immunohistochem Mol Morphol 19: 431-436, 2011.
13. Brenner RM, Slayden OD, Rodgers WH, Critchley HO, Carroll R, Nie XJ and Mah K: Immunocytochemical assessment of mitotic activity with an antibody to phosphorylated histone H3 in the macaque and human endometrium. Hum Reprod 18: 1185-1193, 2003.
14. Solomides CC, Birbe RC, Nicolaou N, Bagley D and Bibbo M: Does mitosis-specific marker phosphohistone H3 help the grading of upper tract urothelial carcinomas in cell blocks? Acta Cytol 56(3): 285-288, 2012.
15. Ohsie SJ, Sarantopoulos GP, Cochran AJ and Binder SW: Immunohistochemical characteristics of melanoma. J Cutan Pathol 35(5): 433-444, 2008.
16. Sasagawa H, Shiozaki A, Iitaka D, Ichikawa D, Komatsu S, Fujiwara H, Okamoto K, Nakashima S, Kinoshita O, Murayama Y, Kuriu Y, Ikoma H, Nakanishi M, Ochiai T, Kokuba Y and Otsuji E: Ki-67 labeling index as an independent prognostic factor in human esophageal squamous cell carcinoma. Esophagus doi: 10.1007/s10388-012-0336-6, 2012.
17. Youssef EM, Matsuda T, Takada N, Osugi H, Higashino M, Kinoshita H, Watanabe T, Katsura Y, Wanibuchi H and Fukushima S: Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer 76: 358-366, 1995.
18. Ikeda G, Isaji S, Chandra B, Watanabe M and Kawarada Y: Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer 86: 1396-1405, 1999.
19. Papakosta V, Vairaktaris E, Vylliotis A, Derka S, Nkenke E, Vassiliou S, Lazaris A, Mourouzis C, Rallis G, Spyridonidou S, Anagnostopoulou S, Perrea D, Donta I, Yapijakis C and Patsouris E: The co-expression of c-MYC and p53 increase and reacshes a plateau early in oral oncogenesis. Anticancer Res 26: 2957-2962, 2006.
20. Goan Y G, Hsu H K, Chang H C, Chou Y P, Chiang K H and Cheng J T: Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients. Ann Thorac Surg 80: 1007-1016, 2005.
21. WAF1 in stage III esophagealsquamous cell carcinoma. Dis Esophagus 25: 7-71, 2012.
22. Sobin L, Gospodarowicz M and Wittekind C (eds.). TNM Classification of Malignant Tumors. 7th ed. Hoboken: Wiley, 2009.
23. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
24. Roninson IB: Oncogenic functions of tumour suppressor p21Waf1/Cip1/Sdi1: association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 179: 1-14, 2002.
25. Gartel AL: Is p21 an oncogene? Mol Cancer Ther 5: 1385-1386, 2006.